Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer

Radiotherapy and Oncology

Volumn 113, Issue 1, 2014, Pages 95-101

  Wopken, Kim ^a   Bijl, Hendrik P ^a   Van Der Schaaf, Arjen ^a   Van Der Laan, Hans Paul ^a   Chouvalova, Olga ^a   Steenbakkers, Roel J H M ^a   Doornaert, Patricia ^b   Slotman, Ben J ^b   Oosting, Sjoukje F ^a   Christianen, Miranda E M C ^a   Van Der Laan, Bernard F A M ^a   Roodenburg, Jan L N ^a   Leemans, C René ^b   Verdonck De Leeuw, Irma M ^b   Langendijk, Johannes A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

(chemo )radiotherapy; Head and neck cancer; IMRT

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; CRICOPHARYNGEUS MUSCLE; ENTERIC FEEDING; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NORMAL TISSUE COMPLICATION PROBABILITY MODEL; ORGANS AT RISK; PAROTID GLAND; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; WEIGHT REDUCTION; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DEGLUTITION DISORDERS; EPIDEMIOLOGY; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RADIOMETRY; THEORETICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY; DEGLUTITION DISORDERS; ENTERAL NUTRITION; EPIDEMIOLOGIC METHODS; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; ORGAN SPARING TREATMENTS; RADIOMETRY; RADIOTHERAPY, INTENSITY-MODULATED; YOUNG ADULT;

EID: 84922610984     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.09.013     Document Type: Article

References (45)

1. Dirix P, Abbeel S, Vanstraelen B, Hermans R, Nuyts S. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2009; 75: 385-92.
2. Agarwal J, Palwe V, Dutta D, et al. Objective assessment of swallowing function after definitive concurrent (chemo)radiotherapy in patients with head and neck cancer. Dysphagia 2011; 26: 399-406.
3. Agarwal J, Dutta D, Palwe V, et al. Prospective subjective evaluation of swallowing function and dietary pattern in head and neck cancers treated with concomitant chemo-radiation. J Cancer Res Ther 2010; 6: 15-21.
4. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 23-8.
5. Nguyen NP, Moltz CC, Frank C, et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004; 15: 383-8.
6. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161-71.
7. Sanguineti G, Gunn GB, Parker BC, Endres EJ, Zeng J, Fiorino C. Weekly dose- volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2011; 79: 52-9.
8. Caudell JJ, Schaner PE, Desmond RA, Meredith RF, Spencer SA, Bonner JA. Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010; 76: 403-9.
9. Citrin D, Mansueti J, Likhacheva A, et al. Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1040-6.
10. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005; 23: 3008-15.
11. Ronis DL, Duffy SA, Fowler KE, Khan MJ, Terrell JE. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 241-8.
12. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60: 1425-39.
13. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007; 68: 1289-98.
14. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010; 28: 2732-8.
15. Eisbruch A, Kim HM, Feng FY, et al. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys 2011; 81: e93-9.
16. van der Laan HP, Christianen ME, Bijl HP, Schilstra C, Langendijk JA. The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: an in silico planning comparative study. Radiother Oncol 2012; 103: 76-81.
17. van der Laan HP, Gawryszuk A, Christianen ME, et al. Swallowing-sparing intensity-modulated radiotherapy for head and neck cancer patients: treatment planning optimization and clinical introduction. Radiother Oncol 2013; 107: 282-7.
18. Amin N, Reddy K, Westerly D, Raben D, Dewitt P, Chen C. Sparing the larynx and esophageal inlet expedites feeding tube removal in patients with stage III- IV oropharyngeal squamous cell carcinoma treated with intensity-modulated radiotherapy. Laryngoscope 2012; 122: 2736-42.
19. Beetz I, Schilstra C, Burlage FR, et al. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: The role of dosimetric and clinical factors. Radiother Oncol 2012; 105: 86-93.
20. Christianen ME, Schilstra C, Beetz I, et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: Results of a prospective observational study. Radiother Oncol 2012; 105: 107-14.
21. Christianen ME, Langendijk JA, Westerlaan HE, van de Water TA, Bijl HP, et al. Delineation of organs at risk involved in swallowing for radiotherapy treatment planning. Radiother Oncol 2011; 101: 394-402.
22. van de Water TA, Bijl HP, Westerlaan HE, Langendijk JA. Delineation guidelines for organs at risk involved in radiation-induced salivary dysfunction and xerostomia. Radiother Oncol 2009; 93: 545-52.
23. Gregoire V, Levendag P, Ang KK, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 2003; 69: 227-36.
24. Gregoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 2006; 79: 15-20.
25. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Statist Soc B 1996; 58: 267-88.
26. Yuan M, Lin Y. Model selection and estimation in regression with grouped variables. J R Statist Soc B 2006; 68: 49-67.
27. Xu CJ, van der Schaaf A, Schilstra C, Langendijk JA, Van't Veld AA. Impact of statistical learning methods on the predictive power of multivariate normal tissue complication probability models. Int J Radiat Oncol Biol Phys 2012; 82: e677-84.
28. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21: 128-38.
29. Vergouwe Y, Moons KG, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol 2010; 172: 971-80.
30. Caglar HB, Tishler RB, Othus M, et al. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 1110-8.
31. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 2007; 85: 64-73.
32. Jensen K, Lambertsen K, Grau C. Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol 2007; 85: 74-82.
33. Vlacich G, Spratt DE, Diaz R, et al. Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensitymodulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. Radiother Oncol 2014; 110: 435-40.
34. Dawes C. Rhythms in salivary flow rate and composition. Int J Chronobiol 1974; 2: 253-79.
35. van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJ, Rasch CR. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol 2008; 3: 41-717X-3-41.
36. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2009; 74: 1-8.
37. Logemann JA, Smith CH, Pauloski BR, et al. Effects of xerostomia on perception and performance of swallow function. Head Neck 2001; 23: 317-21.
38. Tribius S, Sommer J, Prosch C, Bajrovic A, Muenscher A, Blessmann M, Kruell A, Petersen C, Todorovic M, Tennstedt P. Xerostomia after radiotherapy. What matters - mean total dose or dose to each parotid gland? Strahlenther Onkol 2013; 189: 216-22.
39. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA. Unilateral versus bilateral irradiation in squamous cell head and neck cancer in relation to patient-rated xerostomia and sticky saliva. Radiother Oncol 2007; 85: 83-9.
40. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-40.
41. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
42. Madhoun MF, Blankenship MM, Blankenship DM, Krempl GA, Tierney WM. Prophylactic PEG placement in head and neck cancer: how many feeding tubes are unused (and unnecessary)? World J Gastroenterol 2011; 17: 1004-8.
43. Langmore S, Krisciunas GP, Miloro KV, Evans SR, Cheng DM. Does PEG use cause dysphagia in head and neck cancer patients? Dysphagia 2012; 27: 251-9.
44. Mekhail TM, Adelstein DJ, Rybicki LA, Larto MA, Saxton JP, Lavertu P. Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer 2001; 91: 1785-90.
45. Williams GF, Teo MT, Sen M, Dyker KE, Coyle C, Prestwich RJ. Enteral feeding outcomes after chemoradiotherapy for oropharynx cancer: a role for a prophylactic gastrostomy? Oral Oncol 2012; 48: 434-40.